Compare Ascendis Pharma A/S (ASND) vs Gemini Space Station Inc (GEMI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Gemini Space Station Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Gemini Space Station Inc trades at $4.29 (market cap $544.29M). The key difference: Ascendis Pharma A/S is far larger — about 32.6× Gemini Space Station Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals.
| ASND | GEMI | |
|---|---|---|
Market Cap | $17.74B | $544.29M |
Sector | Health | Technology |
52-Week High | $277.18 | $32.52 |
52-Week Low | $163.32 | $3.91 |
Enterprise Value | $18.11B | $534.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Gemini Space Station (GEMI) trades at $4.31, up 1.41% on the day, but remains in a bearish technical trend with key support at $4. The company reported a net loss of $582.81 million in 2025 on revenue of $179.57 million, with negative profit margins and cash flow from operations. Recent news includes a $100 million investment from Winklevoss Capital but also multiple securities class action lawsuits filed against the company.
The outlook is highly speculative. The capital infusion provides near-term funding, but persistent losses, negative cash flow, and legal challenges present significant risks. Analyst consensus is mixed with a $5.88 price target, suggesting potential upside if the company can execute its turnaround, but the fundamental picture remains weak.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →
